Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aduro Biotech (ADRO)

Aduro Biotech (ADRO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 263,529
  • Shares Outstanding, K 80,837
  • Annual Sales, $ 17,260 K
  • Annual Income, $ -82,370 K
  • 60-Month Beta 0.30
  • Price/Sales 15.36
  • Price/Cash Flow N/A
  • Price/Book 4.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.18
  • Number of Estimates 5
  • High Estimate -0.09
  • Low Estimate -0.24
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +21.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.55 +22.35%
on 05/01/20
3.54 -11.86%
on 05/28/20
+0.18 (+6.12%)
since 04/29/20
3-Month
1.87 +66.84%
on 03/18/20
3.59 -13.09%
on 03/05/20
+0.07 (+2.30%)
since 02/28/20
52-Week
0.90 +246.24%
on 10/25/19
4.04 -22.77%
on 02/20/20
-0.33 (-9.57%)
since 05/29/19

Most Recent Stories

More News
Aduro Biotech's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Aduro Biotech.

ADRO : 3.18 (-2.45%)
Aduro Biotech (ADRO) Upgraded to Buy: What Does It Mean for the Stock?

Aduro Biotech (ADRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ADRO : 3.18 (-2.45%)
Is Aduro Biotech (ADRO) Outperforming Other Medical Stocks This Year?

Is (ADRO) Outperforming Other Medical Stocks This Year?

ADRO : 3.18 (-2.45%)
Aduro Biotech to Host Conference Call and Webcast Featuring BION-1301 Data Presented at the 57th ERA-EDTA Virtual Congress

Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL)...

ADRO : 3.18 (-2.45%)
Is Aduro Biotech (ADRO) Stock a Solid Choice Right Now?

Aduro Biotech (ADRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

ADRO : 3.18 (-2.45%)
Aduro Biotech (ADRO) Reports Q1 Loss, Tops Revenue Estimates

Aduro Biotech (ADRO) delivered earnings and revenue surprises of 18.18% and 58.34%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

ADRO : 3.18 (-2.45%)
Aduro Biotech: 1Q Earnings Snapshot

BERKELEY, Calif. (AP) _ Aduro Biotech Inc. (ADRO) on Monday reported a loss of $7.6 million in its first quarter.

ADRO : 3.18 (-2.45%)
Aduro Biotech Provides Business Update and Reports First Quarter 2020 Financial Results

Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL)...

ADRO : 3.18 (-2.45%)
Aduro Biotech (ADRO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Aduro Biotech (ADRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ADRO : 3.18 (-2.45%)
Is Aduro Biotech (ADRO) Outperforming Other Medical Stocks This Year?

Is (ADRO) Outperforming Other Medical Stocks This Year?

ADRO : 3.18 (-2.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ADRO with:

Business Summary

Aduro Biotech, Inc. is an immunotherapy company. The Company develops technology and vaccines for the treatment of cancer and mesothelin-expressing tumors. Its product pipeline includes CRS-207, ADU-623, ADU-214, ADU-741, CDN and STINGVAX which are in different clinical trial. Aduro Biotech, Inc. is...

See More

Key Turning Points

2nd Resistance Point 3.65
1st Resistance Point 3.45
Last Price 3.18
1st Support Level 3.15
2nd Support Level 3.05

See More

52-Week High 4.04
Last Price 3.18
Fibonacci 61.8% 2.84
Fibonacci 50% 2.47
Fibonacci 38.2% 2.10
52-Week Low 0.90

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar